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Summary
Objectives: Between July 2002 and April 2003, over 21 000 individuals were revaccinated against
smallpox by the Israeli Ministry of Health. The objectives of the campaign were to create an
immunized core of first responders, to review vaccination techniques, and to produce vaccinia
immune globulin (VIG).
Methods: The Lister strain of vaccinia virus was used at a concentration of approximately 107 pock-
forming units (PFU)/ml, and was administered by the multiple-puncture technique. The revacci-
nees were from varied ethnic backgrounds, almost all were aged 25—64 years, and all participants
had been vaccinated against smallpox in the past.
Results: The proportion of clinical take was 66.1% (95% CI: 65.2%, 67.0%), similar to past
vaccination programs when take also occurred in approximately two thirds of vaccinees. An
antibody response occurred in 77.7% (95% CI: 74.8%, 80.6%) of all revaccinees: 94.4% (95% CI:
91.8%, 96.3%) of those with clinical take and 56.6% (95% CI: 51.3%, 61.8%) of those without clinical
take. The most common side effects corresponded to symptoms of non-specific viral diseases, and
only a few revaccinees reported serious side effects.
* Corresponding author. Tel.: +972 2 6706814/5/6; fax: +972 2 6706876.
E-mail address: emilia.anis@moh.health.gov.il (E. Anis).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2008.08.007
Conclusions: The campaign achieved all its basic goals and provided useful lessons for any mass-
vaccination programs that might be necessary in the future.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
404 E. Anis et al.Figure 1 Helicopter pipette.Introduction
BetweenJuly 2002 andApril 2003, the IsraeliMinistry ofHealth
revaccinated some 21 000 medical personnel and other first
responders against smallpox. The purposes of this limited
campaign were: (1) to provide a future cadre of personnel
capable of administering smallpox vaccine, investigating sus-
pected smallpox cases, and evacuating and treating smallpox
patients; (2) to review vaccinationmethods, since the routine
vaccination of the civilian population was terminated in 1980;
and (3) to obtain plasma rich in vaccinia antibodies (vaccinia
immune globulin; VIG) for the treatment of defined smallpox
vaccination complications. This report summarizes the high-
lights of the revaccination campaign,with particular emphasis
on the clinical responses and side effects observed, and in
correlation with the serologic responses of the revaccinees.
Methods
The vaccine used was the Lister strain of vaccinia virus, which
was grown on chorioallantoic membranes of fertilized eggs,
and which was produced by the Central Laboratories of the
Israeli Ministry of Health.1 The vaccine antigen concentration
was 107 pock-forming units (PFU)/ml of vaccinia virus, which
was kept frozen at80 8C. Several vaccinationmethods were
considered: jet injector, multiple puncture by lancet, multi-
ple puncture by 23-gauge needle, and multiple pressure by
lancet. As they were not available at the time, bifurcated
needles were not used. After several alternative methods
were explored, the technique chosen was inoculation by
delivery of approximately 20 ml of the vaccine suspension
onto the vaccination site (the skin overlying the deltoid
muscle) using a ‘helicopter’ pipette, followed by 15 brisk
punctures with a 23-gauge needle (Figure 1).
All revaccinees volunteered to participate in the cam-
paign and included first responders such as nurses, physi-
cians, laboratory technicians, pre-hospital emergency staff,
police, firefighters, and military personnel. Most were Israeli
government employees and other individuals working in the
public sector. All declared they had been vaccinated in the
past against smallpox, although only few presented written
documentation of prior vaccination. Thorough examinations
of all candidates were made for scars from prior smallpox
vaccination (including at less conventional sites, such as the
posterior thigh). In all cases of doubt regarding prior inocu-
lation, the decision was made not to vaccinate.
Before being vaccinated, candidates were provided with a
lecture, written materials, and a slide show describing small-
pox, the vaccinia vaccine, contraindications to vaccination,
and possible complications. Participants completed a ques-
tionnaire in which they provided demographic information
and noted relevant medical conditions, particularly the pre-
sence of contraindications. The latter were identical to those
described by the US Centers for Disease Control and Preven-
tion (CDC),2 and included eczema, past or present, in thecandidate or a household member; other active widespread
skin disease in the candidate or a household member; immu-
nosuppression in the candidate or a household member;
pregnancy in the candidate; and a life-threatening allergy
to eggs. Women receiving vaccine were advised to practice
birth control for one month following revaccination. Towards
the end of the campaign additional contraindications were
added according to subsequent CDC recommendations,3 such
as underlying heart disease, selected autoimmune diseases,
and the presence of a pregnant woman in the household.
Vaccine recipients were advised to keep the vaccination
site uncovered under a sleeve, but were permitted to use a
loose gauze dressing if necessary to protect clothing from
oozing transudate. Persons providing direct patient care
were advised to use a loose dressing at all times and to wash
their hands after touching the vaccination site.
A 10 ml blood sample was obtained from the first several
hundred revaccinees prior to vaccination and again approxi-
mately 30 days later, at which time revaccinees were asked
to undergo plasmapheresis or to donate a unit of blood from
which plasma could be extracted.
Table 1 Distribution of revaccinees by age and origin.
Origin Age group (years) Total
1—24 25—34 35—44 45—54 55—64 65+
Israel 109 1436 1766 1730 487 35 5563 (54.7%)
NIS 46 606 710 521 258 14 2155 (21.2%)
All other European countries 9 64 155 431 306 32 997 (9.8%)
Africa 4 25 104 253 106 6 498 (4.9%)
Middle East 2 8 52 163 121 9 355 (3.5%)
South and Central America 0 16 59 108 61 5 249 (2.5%)
North America 2 20 56 91 51 9 229 (2.3%)
Asia 1 2 12 33 60 1 109 (1.1%)
Total 173 (1.7%) 2177 (21.4%) 2914 (28.7%) 3330 (32.8%) 1450 (14.3%) 111 (1.1%) 10 155a (100%)
NIS, New Independent States of the former Soviet Union.
a The table includes revaccinees for whom both age and origin were recorded. In an additional 1316 revaccinees, either age or origin were
unrecorded, resulting in minor variations from the percentages in the text.
Figure 2 Major response (clinical take) by age group.
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via a questionnaire, which was completed 7 to 9 days after
vaccination. Questionnaires were self-completed by medical
professionals; in other cases, a physician or nurse from the
revaccinee’s institution, or from the local public health
office, assisted in the completion of the questionnaire. Clin-
ical ‘take’ (major response) was determined by the appear-
ance of a blister, pustule, ulcer, or scab 7 or more days
following revaccination. We recommended repeat revaccina-
tion to those without clinical take.
Serological studies were performed to determine antibody
titer levels in the Health Ministry’s Central Virology Labora-
tory using a modified microneutralization assay as described
by Somekh et al.4 Contingency analyses were performed to
measure the association between take and demographic
variables as well as various side effects. The rate of side
effects among first versus repeat revaccinations were also
compared using Chi-square statistics. Kappa tests were per-
formed comparing clinical take with paired serological mea-
surements. Multivariate logistic analysis was used to analyze
proportions of take for various institutions and batches of
vaccine.
Results
A total of 21 139 persons were revaccinated. Completed
questionnaires were submitted to the Health Ministry’s
Departments of Epidemiology and Infectious Diseases for
inclusion in a computerized database. The data in this report
are based upon the 11 471 questionnaires that were available
for analysis. These questionnaires came mainly from civilian
revaccinees, most of whom worked in the health sector.
Based on the questionnaires 7456 revaccinees (65%) were
women; almost all revaccinees (97%) were aged 25—64 years;
48.5% of the revaccinees were Israeli born and 27.5% came
from the New Independent States (NIS) of the former Soviet
Union and from other European countries. The age and origin
distributions are shown in Table 1.
Vaccine take
According to the questionnaires submitted, the proportion of
clinical take was 66.1% (95% CI: 65.2%, 67.0%). There was nostatistically significant difference in take between genders
( p = 0.60). Clinical take occurred in 66.4% (95% CI: 64.9%,
67.9%) of men and 65.9% (95% CI: 64.8%, 67.0%) of women.
Except for those aged less than 25 years, the proportion of
clinical take tended to increase with age (Figure 2). The
proportion was 58.3% (95% CI: 56.3%, 60.3%) in revaccinees
aged 25—34 years, 67.1% (95% CI: 66.0%, 68.2%) in those aged
35—54 years, and 71.1% (95% CI: 69.0%, 73.2%) in those aged
55 years and over. In the few revaccinees aged less than 25
years, clinical take averaged 76.9% (95% CI: 70.6%, 82.4%).
The overall p-value of the Chi-square statistic was <0.0001.
There were statistically significant differences in take as a
function of birth country ( p-value of the Pearson Chi-square
statistic of <0.0001). The highest average proportion of take
was recorded among revaccinees born in the NIS at 71.4%
(95% CI: 69.4%, 73.3%); those born in South and Central
America had the lowest recorded proportion of take,
51.4% (95% CI: 45.0%, 57.8%), but this group represented
only 2.5% of revaccinees (Figure 3).
The proportion of clinical take among repeat revaccinees
was 58.4% (95% CI: 52.4%, 64.3%), significantly lower than
among all initial revaccinees, and the p-value measured by
the exact Fisher test was 0.009.
Cold chain
Very different proportions of take were observed between
institutions using the same lot of vaccine. Considering the
Figure 3 Major response (clinical take) by origin.
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revaccinees, in institutions where at least 20 of these doses
were used, the proportion of take varied from less than 35%
to greater than 70% (with a p-value for the Pearson Chi-
square statistic of<0.0001 for each batch). It was discovered
that in the institution with the lowest average proportion of
take, the vaccine was delivered with cold packs, kept refri-
gerated, and then maintained at room temperature for the
duration of the vaccination session. In contrast, in institu-
tions with higher proportions of take, the vaccine was deliv-
ered on dry ice, kept frozen at 80 8C and then stored on ice
throughout the session. We also found that after the vaccine
was defrosted, it had to be used within a 24-hour period in
order to maintain the take level. The instructions regarding
the cold chain were revised accordingly.
Side effects of vaccination
Most recipients (n = 9243 or 80.6%) reported local manifesta-
tions and/or systemic side effects. There was an association
between the rate of local manifestations (other than those
included in the definition of clinical take) and the proportion
of take. Revaccinees without clinical take and repeat revac-
cinees exhibited substantially fewer local and systemic man-
ifestations: 1781 (45.8%) of revaccinees without clinical
take, and 83 (29.75%) of repeat revaccinees, exhibited at
least one local and/or systemic side effect. These findings are
summarized in Tables 2 and 3.
The most commonly reported side effects were those of
non-specific viral diseases such as weakness, fatigue, nausea,Table 2 Local and systemic manifestations with or without major
Type With major respon
Axillary pain, pain at vaccination site, itching 90.3 (89.6, 91.0)
Axillary lymph node enlargement 23.8 (22.8, 24.8)
Fever 10.2 (9.5, 10.9)
Chills 16.6 (15.7, 17.4)
Joint and/or muscle pain 28.0 (27.0, 29.0)
Pustules in other locations 2.3 (2.0, 2.7)
Pustules in household contacts 0.2 (0.1, 0.3)
Weakness and/or fatigue, nausea, headache 52.8 (51.6, 53.9)
Other (mild) complaints 14.4 (13.6, 15.2)
CI, confidence interval.
a Data based on 11 471 revaccinees.
b Pearson Chi-square test.headaches, chills, and joint and/or muscle pain. Revaccinees
were particularly troubled by extensive local swelling and
pain, and several sought medical care and even received
antibiotic treatment. One female revaccineewas hospitalized
with a diagnosis of cellulitis while in Jordan on a visit. There
were 221 instances of inadvertent self-inoculation of vaccine
and 17 instances of accidental spread of vaccine virus to a
healthy household member. In one case, which resulted in
generalized vaccinia, a household member undergoing immu-
nosuppressive therapy was accidentally inoculated. This pati-
ent received vaccinia hyperimmune plasma and recovered.
Thirteen revaccinees experienced serious adverse events,
defined by the need either for a visit to a clinic or emergency
department, or for hospitalization. Of these 13, two exhib-
ited generalized vaccinia, two suffered from erythemamulti-
forme, and two suffered from optic neuritis. Other serious
adverse events included a retinal branch vein occlusion, a
perimyocarditis, a polymyalgia, a localized urticarial erup-
tion, a paresthesia of the fingers, a case of herpes zoster, and
a cervical lymphadenopathy. All except the patient with
polymyalgia and one patient with erythema multiforme
recovered or substantially improved.
Serologic responses
A total of 825 paired samples (in which pre-vaccination and
post-vaccination specimens were taken from the same per-
son) were available for analysis of serological responses in
revaccinees. Among the paired samples, a positive response
of an antibody titer increase of at least four-fold between
pre- and post-vaccination specimens was detected in 77.7%
(95% CI: 74.7%, 80.6%) of revaccinees. There was a statisti-
cally significant difference in serological response between
genders ( p-value of Chi-square statistic = 0.01). A positive
serological response occurred in 71.8% (95% CI: 63.2%, 79.3%)
of men and 81.9% (95% CI: 78.1%, 85.3%) of women. There was
no significant difference in serological response as a function
of age: the proportion was 77.8% (95% CI: 62.9%, 88.8%) in
revaccinees aged 25—34 years, 81.5% (95% CI: 76.9%, 85.6%)
for those aged 35—54 years, and 79.7% (95% CI: 73.7%, 84.9%)
for those aged 55 years and over, with the overall p-value of
the Chi-square statistic being 0.77.
Among revaccinees with clinical take, 94.4% (95% CI:
91.8%, 96.3%) had a positive serological response, compared
with 56.6% (95% CI: 51.3%, 61.8%) for those without clinicalresponse (clinical take).
sea % (95% CI) Without major responsea % (95% CI) p-Valueb
39.0 (37.5, 40.6) <0.0001
3.8 (3.2, 4.5) <0.0001
4.6 (3.9, 5.3) <0.0001
6.2 (5.4, 7.0) <0.0001
13.3 (12.2, 14.4) <0.0001
1.1 (0.8, 1.5) <0.0001
0.1 (0.0, 0.3) 0.6955
27.7 (26.3, 29.2) <0.0001
10.5 (9.6, 11.5) <0.0001
Table 3 Local and systemic manifestations on first vs. repeat revaccination.
Type First revaccinationa %
(95% CI)
Repeat revaccinationb %
(95% CI)
p-Valuec
Axillary pain, pain at vaccination site, itching 72.9 (72.1, 73.7) 66.7 (60.8, 72.2) 0.0207
Axillary lymph node enlargement 17.0 (16.3, 17.7) 16.1 (12.0, 21.0) 0.6992
Fever 8.3 (7.8, 8.8) 4.7 (2.5, 7.8) 0.0290
Chills 13.0 (12.4, 13.7) 7.5 (4.7, 11.3) 0.0067
Joint and/or muscle pain 23.5 (22.7, 24.3) 16.1 (12.0, 21.0) 0.0041
Pustules in other locations 1.9 (1.7, 2.2) 0.7 (0.1, 2.6) 0.1434
Pustules in household contacts 0.15 (0.1, 0.2) 0.0 (0.0, 1.3) 0.5199
Weakness and/or fatigue, nausea, headache 44.3 (43.4, 45.2) 31.9 (26.5, 37.7) <0.0001
Other (mild) complaints 13.0 (12.4, 13.7) 10.0 (6.8, 14.2) 0.1378
CI, confidence interval.
a Data based on 11 471 revaccinees.
b Data based on 279 repeat revaccinees.
c Pearson Chi-square test.
Smallpox revaccination, Israel 407take (Figure 4). This results in a kappa statistic of 0.40, which
indicates a fair to moderate agreement between clinical take
and antibody titer.
The rate of side effects for those with a positive serolo-
gical response was 63.5% (95% CI: 59.5%, 67.4%), and for those
without a positive response it was significantly lower, 35.4%
(95% CI: 27.7%, 43.7%), with an exact Fisher test p-value of
less than 0.0001 (Table 4).
VIG production
The plasma obtained from revaccinees was used to produce
2500 l of VIG, with a total protein concentration of between
4.5% and 5.5%, and an anti-vaccinia titer that exceeded 5000
neutralizing units/ml, as determined by an ELISA test.
Discussion
A smallpox vaccination campaign, in which 21 139 first
responders were revaccinated, was conducted in Israel more
than two decades after the cessation of routine smallpox
vaccination. The results show that the vaccine produced in
Israel had a similar potency to that achieved over 40 yearsFigure 4 Major response (clinicaearlier when, as reported in 1961,5 the overall proportion of
clinical take was also approximately two thirds. However
while the proportion of take in the recent campaign equaled
prior historical levels, it was considerably lower than the
proportions of take recorded in the last US vaccination
campaign, which began in 2002. The proportion of take in
US vaccinees was 95% using 1  108 PFU/ml undiluted vac-
cine,6,7 and it was 81% with vaccine diluted at 1:10,6 the
same concentration that was used in Israel.
There were several differences between the vaccination
campaigns in the USA and Israel: the strains that were used
(the NYCBOH strain in the USA and the Lister strain in Israel);
the vaccine concentration (1  108 PFU/ml in the USA and 1—
2  107 PFU/ml in Israel); the vaccination technique (a
bifurcated needle in the USA and multiple puncture with a
23-gauge beveled needle in Israel); the inclusion of primary
vaccinees in the US campaign (of over 450 000 military
vaccinees, 70.5% were naı¨ve,7 while all participants in the
Israeli campaign had been inoculated previously against
smallpox); and the average time elapsed since the last
vaccination (which was shorter in Israel).8
Balicer et al.9 showed that the use of a bifurcated needle
was not a factor influencing the proportion of take in the
Israeli smallpox vaccination campaign, and Frey et al.10l take) and serologic response.
Table 4 Systemic side effects by major response (clinical take) and serologic response.
Take Serology With systemic side effects Without systemic side effects Total
n % 95% CI n % 95% CI n p-Value
Positive Positive 309 66.0 (61.5, 70.3) 159 34.0 (29.7, 38.5) 468 <0.0000
Positive Negative 14 46.7 (28.3, 65.7) 16 53.3 (34.3, 71.7) 30 0.8555
Negative Positive 67 54.0 (44.9, 63.0) 57 46.0 (37.0, 55.1) 124 0.4191
Negative Negative 38 32.5 (24.1, 41.8) 79 67.5 (58.2, 75.9) 117 0.0002
Total 428 57.9 (54.3, 61.5) 311 42.1 (38.5, 45.7) 739a <0.0000
CI, confidence interval.
a For an additional 86 paired samples, results of clinical take were not recorded.
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among vaccinees receiving 108 PFU/ml as compared with
those receiving 107 PFU/ml. This conclusion is supported by
the results of a study conducted by Couch et al.11 showing
that over a dose range of 106.2—108.2 PFU/ml there were no
significant differences in vaccination success rates. The two
factors that most probably did play a major role in lowering
the proportion of take in Israel, as compared with that in the
USA, were the levels of pre-existing antibodies among vac-
cinees and the average time since last vaccination, which are
important determinants in the duration of protection against
smallpox.12,13 Indeed we noted that pre-vaccination anti-
body titers were generally higher in revaccinees without
clinical take compared to those with clinical take (data
not shown). Similar conclusions were reached by Orr
et al.14 in a study conducted on a sample of military revac-
cinees.
The rate of reported side effects was high, although
serious side effects were rare and no life-threatening side
effects occurred. The most troublesome side effects were
the local manifestations of vaccination. The next most
common side effects were those of non-specific viral dis-
ease, such as fever, malaise, and fatigue. As the revaccina-
tion campaign progressed there were fewer reports of minor
side effects, as medical professionals refamiliarized
themselves with the smallpox vaccination process and its
accompanying problems. Nevertheless, if an emergency
mass campaign were required, in which hundreds of thou-
sands of citizens were to be vaccinated each day, health
authorities would certainly find themselves inundated with
complaints of side effects. The experience gained from this
revaccination campaign points to the importance of ade-
quate training and instruction, as well as the operation of
vaccination information centers to ensure a continuous
flow of information to medical personnel, vaccinees, and
the public.
Generally, there was a good association in the revaccina-
tion campaign between clinical take and the appearance of
antibodies, which were tested in a random subset of the
revaccinees. The laboratory results showed antibody
response in more than 94% of revaccinees with clinical take,
and also in more than 56% of the tested revaccinees who did
not have clinical take. However, the meaning of antibody
response in terms of protection following exposure is
unknown, and cannot be learned at this time. While for some
specialists clinical take will continue to be the gold standard
for smallpox vaccination success, others point to alternative
measures, such as cellular immunity, as preferable criteria. Aquantitative benchmark for protection against variola virus
should be clarified in the future.
Conclusions
The campaign achieved its essential goals, which had been to
revaccinate a cadre of first responders, to review vaccination
techniques, and to obtain high-quality VIG. Nonetheless,
Israeli public health officials are following with interest
the development of new smallpox vaccines that might have
fewer contraindications, result in fewer side effects, and
gain a broader acceptance among medical professionals and
the general public.
Finally, while the World Health Organization declared
smallpox eradicated in 1979, we need to be aware that the
risks of international bioterrorism that gave rise to Israel’s
2002—2003 revaccination campaign oblige public health pro-
fessionals the world over to be prepared, both medically and
logistically, for the reappearance of smallpox in our time.
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